Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR (LADIE)
This study is currently recruiting participants.
Verified January 2013 by Intergroupe Francophone de Cancerologie Thoracique
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique
ClinicalTrials.gov Identifier:
NCT01556191
First received: March 8, 2012
Last updated: January 3, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Lung Cancer is to become the first cause of death related to cancer in France as it's already the case in United States. At Present, Lung Cancer in women and in men is treated similarly. Nevertheless, numerous studies shows that lung cancer in women has specificities : at the time of the diagnosis female patients are younger, there are less clinical signs, clinical stages are earlier, histology is often adenocarcinoma. The link with tabagism is weaker . Sensitivity to tabagism is higher (more cancer in women with the same tabagism). Response rate to chemotherapy is better. Prognosis is better
Numerous hypotheses have been put forward to account for the specific characteristics of female lung cancer described above.
- One hypothesis is that there are different genetic anomalies in women. Some studies show an increase of EGFR mutation and HER2 expression and a decrease of expression of repair enzymes (ERCC1, RRM1, BRCA) which can explain the increase sensitivity to tabagism and to chemotherapy.
- Another hypothesis is that hormones play a role in oncogenesis. Indeed, lung cancer presents hormonal risk factors : pre-menopause, less than 3 kids, short menstrual cycle, hormone replacement therapy. Estrogens would have a deleterious effect on cancer incidence and on survival of lung cancer in women. Cellular and animal models show that ER pathway is activated in lung cancer and participates in oncogenesis.
- Moreover an interaction between RE and EGFR pathway has been demonstrated on lung cancer cell lines and mouse models.
EGFR-TKI have shown benefit in women with wild type EGFR or unknown status (with erlotinib) and in women with EGFR mutations (with gefitinib). In this study, the use of these two treatment will be in accordance with their market authorisations.
The objective of this study is to test the addition of an anti-estrogen (fulvestrant) to EGFR-TKI. Fulvestrant is a pure anti-oestrogen that binds to ER, blocks it and accelerates its breakdown. It has a market authorisation in breast cancer. Furthermore the association between EGFR-TKI and anti-estrogen could have a synergetic effect due to interaction between RE and EGFR pathways .
| Condition | Intervention | Phase |
|---|---|---|
|
Stage IV Lung Cancer |
Drug: Gefitinib Drug: Fulvestrant Drug: Erlotinib |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer |
Resource links provided by NLM:
Further study details as provided by Intergroupe Francophone de Cancerologie Thoracique:
Primary Outcome Measures:
- progression-free survival [ Time Frame: Around nine months ] [ Designated as safety issue: No ]From date of randomization until the date of first progression for EGFR mutated patient
- Progression free survival [ Time Frame: Around three months ] [ Designated as safety issue: No ]From date of randomization until the date of first progression for EGFR wild type patients
Secondary Outcome Measures:
- toxicity of EGFR-TKI and fulvestrant [ Time Frame: Around three months ] [ Designated as safety issue: Yes ]The number of patients for whom at least an adverse event will have been reported, the number of events, according to the relation to the treatment, the intensity, and the cycle of appearance for EGFR WT patients
- Response rate [ Time Frame: Around three months ] [ Designated as safety issue: No ]For EGFR WT patients
- Overall survival [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
- Quality of life [ Time Frame: Around three months ] [ Designated as safety issue: No ]For EGFR WT patients
- toxicity of EGFR-TKI and fulvestrant [ Time Frame: Around Nine months ] [ Designated as safety issue: Yes ]The number of patients for whom at least an adverse event will have been reported, the number of events, according to the relation to the treatment, the intensity, and the cycle of appearance for EGFR mutated patients
- Response rate [ Time Frame: Around nine months ] [ Designated as safety issue: No ]For EGFR-Mutated patients
- Quality of life [ Time Frame: Around nine months ] [ Designated as safety issue: No ]For EGFR mutated patients
| Estimated Enrollment: | 358 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | May 2016 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Gefinitib + Fulvestrant (patient with EGFR mutations) |
Drug: Gefitinib
250 mg per day (oral)
Drug: Fulvestrant
500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
|
| Active Comparator: Erlotinib (wild type patients) |
Drug: Erlotinib
150 mg per day (oral)
|
| Experimental: Erlotinib + Fulvestrant (wild type patients) |
Drug: Fulvestrant
500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
Drug: Erlotinib
150 mg per day (oral)
|
| Active Comparator: Gefinib (patient with EGFR mutations) |
Drug: Gefitinib
250 mg per day (oral)
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically confirmed predominant non-squamous, non-small cell lung cancer
- The presence of analysable tissue for the research of EGFR activating mutation. Analysis must be performed in INCa-labelled laboratories or platforms according to a validated technique
- Not suitable for radiation, inoperable stage III or stage IV
- Patients with an EGFR mutation must never have taken chemotherapy or must be in progression after only one previous line of chemotherapy (including maintenance). Patients without an EGFR mutation must have received one or two lines of chemotherapy beforehand. Maintenance chemotherapy is not considered to be a treatment line. Adjuvant chemotherapy is not considered to be a first line of treatment if it dates back to over a year
- Female
- Menopausal: older than 60 years of age or history of ovariectomy or younger than 60 years old with amenorrhoea for more than 12 months or an FSH rate that corresponds to a post-menopausal rate (according to the laboratory)
Exclusion Criteria:
- History of cancer except for skin cancer or cancer dating from over five years ago and considered to be cured
- Known or suspected Cerebral metastases or spinal cord compression unless they are asymptomatic without treatment or stable after being treated by surgery and/or radiation therapy. Corticosteroid treatments for symptoms must have discontinued for more than four weeks
- Pregnancy and breast-feeding
- Patient taking hormone replacement therapy for menopause that has not been stopped two weeks before the start of the trial treatment
- A change in bone marrow, kidney and liver functions inconsistent with treatment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01556191
Show 58 Study Locations
Contacts
| Contact: Franck MORIN | contact@ifct.fr | |
| Contact: Elodie AMOUR | contact@ifct.fr |
Show 58 Study LocationsSponsors and Collaborators
Intergroupe Francophone de Cancerologie Thoracique
Investigators
| Principal Investigator: | Julien MAZIERES, MD, phD | University Hospital, Toulouse |
More Information
Additional Information:
No publications provided
| Responsible Party: | Intergroupe Francophone de Cancerologie Thoracique |
| ClinicalTrials.gov Identifier: | NCT01556191 History of Changes |
| Other Study ID Numbers: | IFCT-1003 |
| Study First Received: | March 8, 2012 |
| Last Updated: | January 3, 2013 |
| Health Authority: | France: L’Agence nationale de sécurité du médicament et des produits de santé |
Keywords provided by Intergroupe Francophone de Cancerologie Thoracique:
|
lung cancer women |
Additional relevant MeSH terms:
|
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Estrogen Antagonists Fulvestrant Estrogen Receptor Modulators Estrogens Gefitinib |
Erlotinib Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Hormones Antineoplastic Agents Therapeutic Uses Antineoplastic Agents, Hormonal Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 19, 2013